***Background.*** Ceftolozane/tazobactam demonstrates excellent activity in vitro against Gram-negative pathogens, including extended spectrum β-lactamase--producing Enterobacteriaceae and multidrug-resistant *Pseudomonas aeruginosa*. The efficacy of ceftolozane/tazobactam in the subset of patients with cUTI, including pyelonephritis, caused by levofloxacin (LVX)-resistant pathogens was examined from pooled efficacy data of 2 Phase 3, randomized, controlled, double-blind trials (NCT01345929 and NCT01345955).

***Methods.*** Hospitalized patients ≥18 years old with pyuria and clinical symptoms of cUTI were randomized to either intravenous ceftolozane/tazobactam 1.5 g every 8 hours or intravenous LVX 750 mg/day for 7 days, prior to availability of susceptibility data. Primary outcome was the composite microbiological eradication and clinical cure (composite cure) rate at the test-of-cure (TOC) visit 5-9 days after the end of therapy in the microbiological modified intent-to-treat (mMITT) and microbiologically evaluable (ME) populations.

***Results.*** A total of 1083 patients were enrolled, 800 were included in the mMITT population, and 212 had LVX-resistant baseline uropathogens; 176/212 were susceptible to ceftolozane/tazobactam. Ceftolozane/tazobactam demonstrated significantly higher composite cure rates and per-pathogen microbiological eradication rates vs LVX in the mMITT and ME populations (Table).

***Conclusion.*** Ceftolozane/tazobactam demonstrated superior composite cure rates vs LVX in cUTI caused by LVX-resistant pathogens. Ceftolozane/tazobactam may offer an alternative treatment for cUTI in settings of increasing fluoroquinolone resistance among common uropathogens.
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  Outcomes in the LVX-resistant Population at TOC     Population     Ceftolozane /Tazobactam % (n/N)   LVX % (n/N)            Difference % (95% Confidence Interval)
  --------------------------------------------------- -------------- --------------------------------- ---------------------- ----------------------------------------
  **Composite Cure Rate**                             mMITT          60.0 (60/100)                     39.3 (44/112)          20.7 (7.23 to 33.17)
  ME                                                  64.0 (57/89)   43.4 (43/99)                      20.6 (6.33 to 33.72)   
  **Per-pathogen Microbiological Eradication Rate**   ME                                                                      
   Enterobacteriaceae                                                71.4 (55/77)                      45.2 (38/84)           26.2 (10.96 to 39.72)
    *Escherichia coli*                                               72.9 (43/59)                      44.1 (30/68)           28.8 (11.59 to 43.55)
    *Klebsiella pneumoniae*                                          81.8 (9/11)                       30.0 (3/10)            51.8 (9.50 to 75.05)
   *P. aeruginosa*                                                   100.0 (3/3)                       37.5 (3/8)             62.5 (-2.09 to 86.32)
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